Fibromyalgia cell therapy remains highly speculative. Patients with severe, treatment-refractory fibromyalgia who have exhausted conventional therapies (pregabalin, duloxetine, pacing, CBT) might consider it as an exploratory option, but the evidence base is minimal and risks are not well characterised. Mainstream rheumatology does not endorse it, and mainstream guidelines continue to recommend multimodal conventional therapy.
Fibromyalgia is a disorder of central pain processing characterised by widespread musculoskeletal pain, fatigue, and sleep disturbance, often accompanied by cognitive difficulties ('fibro fog'). No primary tissue damage is evident; instead, dysregulation of pain-signal amplification in the spinal cord and brain—low serotonin, elevated substance P, sensitised pain receptors—perpetuates the syndrome. The condition predominantly affects women and is often triggered by trauma, infection, or stress. Cell therapy exploration in fibromyalgia is nascent; placental MSCs and their secreted exosomes are being investigated for immunomodulatory properties (shifting immune response away from pro-inflammatory cytokine production) and for potential neuromodulation through delivery of anti-inflammatory molecules to the central nervous system. The hypothesis is that systemic cellular or exosome infusion might dampen the amplified pain state and restore normal sleep and mood regulation.
Am I a candidate? → · Fibromyalgia & Chronic Fatigue: full overview → · Fibromyalgia & Chronic Fatigue cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估